Next Article in Journal
Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model
Next Article in Special Issue
Understanding the Molecular Genetics of Basal Cell Carcinoma
Previous Article in Journal
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessCase Report
Int. J. Mol. Sci. 2017, 18(8), 1663; doi:10.3390/ijms18081663

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

1
Department of Dermatology, University of California San Diego, San Diego, CA 92122, USA
2
Department of Medicine, Division of Hematology/Oncology, University of California San Diego, La Jolla, CA 92093, USA
3
Center of Personalized Cancer Therapy, University of California San Diego, La Jolla, CA 92093, USA
4
Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, CA 92093, USA
5
Medical Hospital, Central Clinical Facilities, Cancer Center, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 7 July 2017 / Revised: 26 July 2017 / Accepted: 31 July 2017 / Published: 31 July 2017
(This article belongs to the Special Issue Basal Cell Carcinoma)
View Full-Text   |   Download PDF [1394 KB, uploaded 1 August 2017]   |  

Abstract

Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate resistance to these agents. We describe a man with metastatic basal cell carcinoma who did not respond well to vismodegib and sonidegib. Next generation sequencing of his metastatic liver tumor demonstrated a high tumor mutational burden (103 mutations per megabase) and the genomic amplification of PD-L1, both of which are features that predict response to anti-PD1/PD-L1 immunotherapy. Treatment with nivolumab, an anti-PD1 checkpoint inhibitor, resulted in near complete remission. Yet, he developed new primary cutaneous basal cell carcinomas while receiving immunotherapy and while his metastatic disease showed an ongoing response. His new superficial skin cancer had a lower tumor mutational burden (45 mutations per megabase) than the metastatic disease. Since immunotherapy response rates are higher in patients with more genomically complex tumors, our observations suggest that, in contrast with the premise of earlier treatment is better, which holds true for targeted and cytotoxic therapies, immunotherapy may be better suited to more advanced disease. View Full-Text
Keywords: basal; carcinoma; cell; cutaneous; immunotherapy; metastatic; nivolumab basal; carcinoma; cell; cutaneous; immunotherapy; metastatic; nivolumab
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cohen, P.R.; Kato, S.; Goodman, A.M.; Ikeda, S.; Kurzrock, R. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int. J. Mol. Sci. 2017, 18, 1663.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top